KYMR Latest Press Releases

-- October 29, 2026 --

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial Globe Newswire 7:00 AM

-- October 28, 2026 --

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026 Globe Newswire 4:01 PM

-- October 22, 2026 --

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 Globe Newswire 4:01 PM

-- October 12, 2026 --

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PRNewswire 9:31 AM

-- September 30, 2026 --

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm PRNewswire 8:59 AM

-- September 2, 2026 --

Kymera Therapeutics to Participate in Upcoming September Investor Conferences Globe Newswire 4:01 PM

-- September 1, 2026 --

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses Globe Newswire 7:00 AM

-- August 5, 2026 --

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Globe Newswire 7:00 AM

-- July 28, 2026 --

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 Globe Newswire 4:01 PM

-- July 27, 2026 --

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer Globe Newswire 4:01 PM

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm PRNewswire 8:49 AM

-- July 17, 2026 --

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm Globe Newswire 4:21 PM

-- July 16, 2026 --

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PRNewswire 11:13 AM

-- July 7, 2026 --

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader Globe Newswire 7:00 AM

-- June 25, 2026 --

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 Globe Newswire 7:00 AM

-- June 24, 2026 --

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors Globe Newswire 4:01 PM

-- June 12, 2026 --

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes